ID   S52A3_HUMAN             Reviewed;         469 AA.
AC   Q9NQ40; A8K6P1; Q5W1A0; Q5W1A1; Q8NCL7; Q96GD5;
DT   10-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 4.
DT   10-MAY-2017, entry version 133.
DE   RecName: Full=Solute carrier family 52, riboflavin transporter, member 3;
DE   AltName: Full=Riboflavin transporter 2;
DE            Short=hRFT2;
GN   Name=SLC52A3; Synonyms=C20orf54, RFT2, RFVT3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Mammary gland, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   LEU-267; MET-278 AND VAL-303.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION.
RX   PubMed=19122205; DOI=10.1093/jb/mvn181;
RA   Yamamoto S., Inoue K., Ohta K.Y., Fukatsu R., Maeda J.Y., Yoshida Y.,
RA   Yuasa H.;
RT   "Identification and functional characterization of rat riboflavin
RT   transporter 2.";
RL   J. Biochem. 145:437-443(2009).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=20463145; DOI=10.3945/jn.110.122911;
RA   Yao Y., Yonezawa A., Yoshimatsu H., Masuda S., Katsura T., Inui K.;
RT   "Identification and comparative functional characterization of a new
RT   human riboflavin transporter hRFT3 expressed in the brain.";
RL   J. Nutr. 140:1220-1226(2010).
RN   [6]
RP   SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BOND, AND MUTAGENESIS OF
RP   CYS-326; CYS-386; ARG-455; CYS-463 AND CYS-467.
RX   PubMed=21512156; DOI=10.1152/ajpgi.00120.2011;
RA   Subramanian V.S., Rapp L., Marchant J.S., Said H.M.;
RT   "Role of cysteine residues in cell surface expression of the human
RT   riboflavin transporter-2 (hRFT2) in intestinal epithelial cells.";
RL   Am. J. Physiol. 301:G100-G109(2011).
RN   [7]
RP   INVOLVEMENT IN FALOND, INVOLVEMENT IN BVVLS1, AND VARIANT BVVLS1
RP   ARG-17.
RX   PubMed=21110228; DOI=10.1007/s10545-010-9242-z;
RA   Bosch A.M., Abeling N.G., Ijlst L., Knoester H., van der Pol W.L.,
RA   Stroomer A.E., Wanders R.J., Visser G., Wijburg F.A., Duran M.,
RA   Waterham H.R.;
RT   "Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with
RT   a riboflavin transporter defect mimicking mild MADD: a new inborn
RT   error of metabolism with potential treatment.";
RL   J. Inherit. Metab. Dis. 34:159-164(2011).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24264046; DOI=10.1152/ajpgi.00349.2013;
RA   Yoshimatsu H., Yonezawa A., Yao Y., Sugano K., Nakagawa S., Omura T.,
RA   Matsubara K.;
RT   "Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin
RT   absorption.";
RL   Am. J. Physiol. 306:G102-G110(2014).
RN   [9]
RP   VARIANTS BVVLS1 LYS-36; TRP-132; LEU-224; ALA-413 AND LEU-457, AND
RP   VARIANT MET-350.
RX   PubMed=20206331; DOI=10.1016/j.ajhg.2010.02.006;
RA   Green P., Wiseman M., Crow Y.J., Houlden H., Riphagen S., Lin J.P.,
RA   Raymond F.L., Childs A.M., Sheridan E., Edwards S., Josifova D.J.;
RT   "Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with
RT   deafness, is caused by mutations in c20orf54.";
RL   Am. J. Hum. Genet. 86:485-489(2010).
RN   [10]
RP   VARIANTS BVVLS1 THR-28 AND LYS-71.
RX   PubMed=20920669; DOI=10.1016/j.ajhg.2010.05.021;
RA   Johnson J.O., Gibbs J.R., Van Maldergem L., Houlden H.,
RA   Singleton A.B.;
RT   "Exome sequencing in Brown-Vialetto-van Laere syndrome.";
RL   Am. J. Hum. Genet. 87:567-569(2010).
RN   [11]
RP   VARIANTS BVVLS1 SER-21; HIS-220; VAL-312 AND ASP-375.
RX   PubMed=22718020; DOI=10.1038/jhg.2012.70;
RA   Dezfouli M.A., Yadegari S., Nafissi S., Elahi E.;
RT   "Four novel C20orf54 mutations identified in Brown-Vialetto-Van Laere
RT   syndrome patients.";
RL   J. Hum. Genet. 57:613-617(2012).
RN   [12]
RP   CHARACTERIZATION OF VARIANTS BVVLS1 ARG-17; THR-28; LYS-36; LYS-71 AND
RP   TRP-132, CHARACTERIZATION OF VARIANT MET-350, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=22273710; DOI=10.1016/j.ymgme.2011.12.021;
RA   Nabokina S.M., Subramanian V.S., Said H.M.;
RT   "Effect of clinical mutations on functionality of the human riboflavin
RT   transporter-2 (hRFT-2).";
RL   Mol. Genet. Metab. 105:652-657(2012).
RN   [13]
RP   VARIANTS BVVLS1 ASP-58; TRP-266; SER-319 AND ALA-413, AND VARIANT
RP   VAL-303.
RX   PubMed=22824638; DOI=10.1016/j.nmd.2012.05.007;
RA   Ciccolella M., Catteruccia M., Benedetti S., Moroni I., Uziel G.,
RA   Pantaleoni C., Chiapparini L., Bizzi A., D'Amico A., Fattori F.,
RA   Salsano M.L., Pastore A., Tozzi G., Piemonte F., Bertini E.;
RT   "Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a
RT   clinical, biochemical and genetic study.";
RL   Neuromuscul. Disord. 22:1075-1082(2012).
RN   [14]
RP   VARIANT BVVLS1 VAL-330.
RX   PubMed=22633641; DOI=10.1016/j.pediatrneurol.2012.03.008;
RA   Koy A., Pillekamp F., Hoehn T., Waterham H., Klee D., Mayatepek E.,
RA   Assmann B.;
RT   "Brown-Vialetto-Van Laere syndrome: a riboflavin-unresponsive patient
RT   with a novel mutation in the C20orf54 gene.";
RL   Pediatr. Neurol. 46:407-409(2012).
RN   [15]
RP   VARIANT BVVLS1 SER-21, CHARACTERIZATION OF VARIANT BVVLS1 SER-21,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=27702554; DOI=10.1016/j.cca.2016.09.022;
RA   Udhayabanu T., Subramanian V.S., Teafatiller T., Gowda V.K.,
RA   Raghavan V.S., Varalakshmi P., Said H.M., Ashokkumar B.;
RT   "SLC52A2 [p.P141T] and SLC52A3 [p.N21S] causing Brown-Vialetto-Van
RT   Laere syndrome in an Indian patient: First genetically proven case
RT   with mutations in two riboflavin transporters.";
RL   Clin. Chim. Acta 462:210-214(2016).
CC   -!- FUNCTION: Transporter for riboflavin, which must be obtained as a
CC       nutrient via intestinal absorption. Riboflavin transport is Na(+)-
CC       independent at low pH but significantly reduced by Na(+) depletion
CC       under neutral pH conditions. Activity is strongly inhibited by
CC       riboflavin analogs, such as lumiflavin, flavin mononucleotide
CC       (FMN), flavin adenine dinucleotide (FAD), by methylene blue, and
CC       to a lesser extent by amiloride. {ECO:0000269|PubMed:20463145,
CC       ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:24264046,
CC       ECO:0000269|PubMed:27702554}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.98 uM for riboflavin {ECO:0000269|PubMed:20463145};
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:20463145, ECO:0000269|PubMed:21512156,
CC       ECO:0000269|PubMed:24264046}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20463145}. Cell membrane
CC       {ECO:0000269|PubMed:22273710, ECO:0000269|PubMed:27702554}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQ40-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQ40-2; Sequence=VSP_003814, VSP_003815;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in testis. Highly
CC       expressed in small intestine and prostate.
CC       {ECO:0000269|PubMed:20463145}.
CC   -!- DISEASE: Brown-Vialetto-Van Laere syndrome 1 (BVVLS1)
CC       [MIM:211530]: A rare neurologic disorder characterized by
CC       sensorineural hearing loss and a variety of cranial nerve palsies,
CC       which develop over a relatively short period of time in a
CC       previously healthy individual. Sensorineural hearing loss may
CC       precede the neurological signs. The course is invariably
CC       progressive, but the rate of decline is variable within and
CC       between families. With disease evolution, long tract signs, lower
CC       motor neuron signs, cerebellar ataxia and lower cranial nerve
CC       (III-VI) palsies develop, giving rise to a complex picture
CC       resembling amyotrophic lateral sclerosis. Diaphragmatic weakness
CC       and respiratory compromise are some of the most distressing
CC       features, leading to recurrent chest infections and respiratory
CC       failure, which are often the cause of patients' demise.
CC       {ECO:0000269|PubMed:20206331, ECO:0000269|PubMed:20920669,
CC       ECO:0000269|PubMed:21110228, ECO:0000269|PubMed:22273710,
CC       ECO:0000269|PubMed:22633641, ECO:0000269|PubMed:22718020,
CC       ECO:0000269|PubMed:22824638, ECO:0000269|PubMed:27702554}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Fazio-Londe disease (FALOND) [MIM:211500]: A rare
CC       neurological disease characterized by progressive weakness of the
CC       muscles innervated by cranial nerves of the lower brain stem. It
CC       may present in childhood with severe neurological deterioration
CC       with hypotonia, respiratory insufficiency leading to premature
CC       death, or later in life with bulbar weakness which progresses to
CC       involve motor neurons throughout the neuroaxis. Clinical
CC       manifestations include dysarthria, dysphagia, facial weakness,
CC       tongue weakness, and fasciculations of the tongue and facial
CC       muscles. {ECO:0000269|PubMed:21110228}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the riboflavin transporter family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-5 is the initiator.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK074650; BAC11113.1; -; mRNA.
DR   EMBL; AK291706; BAF84395.1; -; mRNA.
DR   EMBL; AL118502; CAH73077.2; -; Genomic_DNA.
DR   EMBL; AL118502; CAH73078.2; -; Genomic_DNA.
DR   EMBL; BC009750; AAH09750.2; -; mRNA.
DR   CCDS; CCDS13007.1; -. [Q9NQ40-1]
DR   RefSeq; NP_212134.3; NM_033409.3. [Q9NQ40-1]
DR   RefSeq; XP_005260712.1; XM_005260655.3. [Q9NQ40-1]
DR   RefSeq; XP_011527450.1; XM_011529148.1. [Q9NQ40-1]
DR   UniGene; Hs.283865; -.
DR   ProteinModelPortal; Q9NQ40; -.
DR   STRING; 9606.ENSP00000217254; -.
DR   TCDB; 2.A.125.1.2; the eukaryotic riboflavin transporter (e-rft) family.
DR   PhosphoSitePlus; Q9NQ40; -.
DR   BioMuta; SLC52A3; -.
DR   DMDM; 82654931; -.
DR   PaxDb; Q9NQ40; -.
DR   PeptideAtlas; Q9NQ40; -.
DR   PRIDE; Q9NQ40; -.
DR   DNASU; 113278; -.
DR   Ensembl; ENST00000217254; ENSP00000217254; ENSG00000101276. [Q9NQ40-1]
DR   Ensembl; ENST00000381944; ENSP00000371370; ENSG00000101276. [Q9NQ40-2]
DR   Ensembl; ENST00000632431; ENSP00000488723; ENSG00000101276. [Q9NQ40-1]
DR   GeneID; 113278; -.
DR   KEGG; hsa:113278; -.
DR   UCSC; uc002wed.5; human. [Q9NQ40-1]
DR   CTD; 113278; -.
DR   DisGeNET; 113278; -.
DR   GeneCards; SLC52A3; -.
DR   H-InvDB; HIX0015557; -.
DR   HGNC; HGNC:16187; SLC52A3.
DR   HPA; HPA049391; -.
DR   MalaCards; SLC52A3; -.
DR   MIM; 211500; phenotype.
DR   MIM; 211530; phenotype.
DR   MIM; 613350; gene.
DR   neXtProt; NX_Q9NQ40; -.
DR   OpenTargets; ENSG00000101276; -.
DR   Orphanet; 97229; Riboflavin transporter deficiency.
DR   PharmGKB; PA25764; -.
DR   eggNOG; KOG4255; Eukaryota.
DR   eggNOG; ENOG410YE1U; LUCA.
DR   GeneTree; ENSGT00390000003774; -.
DR   HOGENOM; HOG000247012; -.
DR   HOVERGEN; HBG051170; -.
DR   InParanoid; Q9NQ40; -.
DR   KO; K14620; -.
DR   OMA; AMFLHFT; -.
DR   OrthoDB; EOG091G0BZA; -.
DR   PhylomeDB; Q9NQ40; -.
DR   TreeFam; TF314820; -.
DR   Reactome; R-HSA-196843; Vitamin B2 (riboflavin) metabolism.
DR   GeneWiki; C20orf54; -.
DR   GenomeRNAi; 113278; -.
DR   PRO; PR:Q9NQ40; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101276; -.
DR   CleanEx; HS_C20orf54; -.
DR   ExpressionAtlas; Q9NQ40; baseline and differential.
DR   Genevisible; Q9NQ40; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032217; F:riboflavin transporter activity; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0006771; P:riboflavin metabolic process; TAS:Reactome.
DR   GO; GO:0032218; P:riboflavin transport; IDA:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB.
DR   InterPro; IPR009357; Riboflavin_transptr.
DR   PANTHER; PTHR12929; PTHR12929; 1.
DR   Pfam; PF06237; DUF1011; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome; Deafness;
KW   Disease mutation; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    469       Solute carrier family 52, riboflavin
FT                                transporter, member 3.
FT                                /FTId=PRO_0000042636.
FT   TOPO_DOM      1      2       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      3     23       Helical. {ECO:0000255}.
FT   TOPO_DOM     24     43       Extracellular. {ECO:0000255}.
FT   TRANSMEM     44     64       Helical. {ECO:0000255}.
FT   TOPO_DOM     65     71       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     72     92       Helical. {ECO:0000255}.
FT   TOPO_DOM     93     97       Extracellular. {ECO:0000255}.
FT   TRANSMEM     98    118       Helical. {ECO:0000255}.
FT   TOPO_DOM    119    137       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    138    158       Helical. {ECO:0000255}.
FT   TOPO_DOM    159    220       Extracellular. {ECO:0000255}.
FT   TRANSMEM    221    241       Helical. {ECO:0000255}.
FT   TOPO_DOM    242    292       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    293    313       Helical. {ECO:0000255}.
FT   TOPO_DOM    314    335       Extracellular. {ECO:0000255}.
FT   TRANSMEM    336    356       Helical. {ECO:0000255}.
FT   TOPO_DOM    357    359       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    360    380       Helical. {ECO:0000255}.
FT   TOPO_DOM    381    396       Extracellular. {ECO:0000255}.
FT   TRANSMEM    397    417       Helical. {ECO:0000255}.
FT   TOPO_DOM    418    427       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    428    448       Helical. {ECO:0000255}.
FT   TOPO_DOM    449    469       Extracellular. {ECO:0000255}.
FT   MOD_RES     251    251       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q4FZU9}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    168    168       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    386    463       {ECO:0000305|PubMed:21512156}.
FT   VAR_SEQ     401    415       ASWVLFSGCLSYVKV -> SIRPVGLLPLRTPHP (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_003814.
FT   VAR_SEQ     416    469       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_003815.
FT   VARIANT      17     17       W -> R (in BVVLS1; loss of riboflavin
FT                                transport; no effect on localization to
FT                                cell membrane; does not affect protein
FT                                abundance; dbSNP:rs797045190).
FT                                {ECO:0000269|PubMed:21110228,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_077422.
FT   VARIANT      21     21       N -> S (in BVVLS1; loss of localization
FT                                to cell membrane; loss of riboflavin
FT                                transport; dbSNP:rs199588390).
FT                                {ECO:0000269|PubMed:22718020,
FT                                ECO:0000269|PubMed:27702554}.
FT                                /FTId=VAR_077423.
FT   VARIANT      28     28       P -> T (in BVVLS1; loss of localization
FT                                to cell membrane; loss of riboflavin
FT                                transport; does not affect protein
FT                                abundance; dbSNP:rs267606688).
FT                                {ECO:0000269|PubMed:20920669,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_077424.
FT   VARIANT      36     36       E -> K (in BVVLS1; loss of localization
FT                                to cell membrane; loss of riboflavin
FT                                transport; does not affect protein
FT                                abundance; dbSNP:rs267606686).
FT                                {ECO:0000269|PubMed:20206331,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_063694.
FT   VARIANT      58     58       V -> D (in BVVLS1; dbSNP:rs797045192).
FT                                {ECO:0000269|PubMed:22824638}.
FT                                /FTId=VAR_077425.
FT   VARIANT      71     71       E -> K (in BVVLS1; loss of localization
FT                                to cell membrane; loss of riboflavin
FT                                transport; does not affect protein
FT                                abundance; dbSNP:rs267606683).
FT                                {ECO:0000269|PubMed:20920669,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_077426.
FT   VARIANT      74     74       I -> M (in dbSNP:rs35655964).
FT                                /FTId=VAR_053565.
FT   VARIANT     132    132       R -> W (in BVVLS1; loss of localization
FT                                to cell membrane; loss of riboflavin
FT                                transport; does not affect protein
FT                                abundance; dbSNP:rs267606684).
FT                                {ECO:0000269|PubMed:20206331,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_063695.
FT   VARIANT     174    174       D -> G (in dbSNP:rs6054614).
FT                                /FTId=VAR_053566.
FT   VARIANT     220    220       P -> H (in BVVLS1; unknown pathological
FT                                significance; dbSNP:rs797045194).
FT                                {ECO:0000269|PubMed:22718020}.
FT                                /FTId=VAR_077427.
FT   VARIANT     224    224       F -> L (in BVVLS1; dbSNP:rs267606685).
FT                                {ECO:0000269|PubMed:20206331}.
FT                                /FTId=VAR_063696.
FT   VARIANT     266    266       R -> W (in BVVLS1; unknown pathological
FT                                significance; dbSNP:rs370499474).
FT                                {ECO:0000269|PubMed:22824638}.
FT                                /FTId=VAR_077428.
FT   VARIANT     267    267       P -> L (in dbSNP:rs3746804).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_053567.
FT   VARIANT     278    278       T -> M (in dbSNP:rs3746803).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_053568.
FT   VARIANT     303    303       I -> V (in dbSNP:rs3746802).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:22824638}.
FT                                /FTId=VAR_053569.
FT   VARIANT     312    312       A -> V (in BVVLS1; unknown pathological
FT                                significance; dbSNP:rs752218005).
FT                                {ECO:0000269|PubMed:22718020}.
FT                                /FTId=VAR_077429.
FT   VARIANT     319    319       P -> S (in BVVLS1; unknown pathological
FT                                significance; dbSNP:rs797045195).
FT                                {ECO:0000269|PubMed:22824638}.
FT                                /FTId=VAR_077430.
FT   VARIANT     330    330       G -> V (in BVVLS1; unknown pathological
FT                                significance; dbSNP:rs797045196).
FT                                {ECO:0000269|PubMed:22633641}.
FT                                /FTId=VAR_077431.
FT   VARIANT     350    350       L -> M (polymorphism; no effect on
FT                                riboflavin transport; no effect on
FT                                localization to cell membrane;
FT                                dbSNP:rs76947760).
FT                                {ECO:0000269|PubMed:20206331,
FT                                ECO:0000269|PubMed:22273710}.
FT                                /FTId=VAR_063698.
FT   VARIANT     375    375       G -> D (in BVVLS1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22718020}.
FT                                /FTId=VAR_077432.
FT   VARIANT     411    411       S -> R (in dbSNP:rs910857).
FT                                /FTId=VAR_063699.
FT   VARIANT     413    413       V -> A (in BVVLS1; dbSNP:rs267606687).
FT                                {ECO:0000269|PubMed:20206331,
FT                                ECO:0000269|PubMed:22824638}.
FT                                /FTId=VAR_063700.
FT   VARIANT     457    457       F -> L (in BVVLS1; dbSNP:rs779750163).
FT                                {ECO:0000269|PubMed:20206331}.
FT                                /FTId=VAR_063701.
FT   MUTAGEN     326    326       C->A: No effect on cell surface
FT                                localization.
FT                                {ECO:0000269|PubMed:21512156}.
FT   MUTAGEN     386    386       C->A: Abolishes cell surface
FT                                localization.
FT                                {ECO:0000269|PubMed:21512156}.
FT   MUTAGEN     455    455       R->A: No effect on cell surface
FT                                localization.
FT                                {ECO:0000269|PubMed:21512156}.
FT   MUTAGEN     463    463       C->A: Abolishes cell surface
FT                                localization.
FT                                {ECO:0000269|PubMed:21512156}.
FT   MUTAGEN     467    467       C->A: Abolishes cell surface
FT                                localization.
FT                                {ECO:0000269|PubMed:21512156}.
FT   CONFLICT     11     11       V -> D (in Ref. 1; BAF84395).
FT                                {ECO:0000305}.
FT   CONFLICT    199    199       L -> P (in Ref. 1; BAC11113).
FT                                {ECO:0000305}.
SQ   SEQUENCE   469 AA;  50805 MW;  239ED67348C93739 CRC64;
     MAFLMHLLVC VFGMGSWVTI NGLWVELPLL VMELPEGWYL PSYLTVVIQL ANIGPLLVTL
     LHHFRPSCLS EVPIIFTLLG VGTVTCIIFA FLWNMTSWVL DGHHSIAFLV LTFFLALVDC
     TSSVTFLPFM SRLPTYYLTT FFVGEGLSGL LPALVALAQG SGLTTCVNVT EISDSVPSPV
     PTRETDIAQG VPRALVSALP GMEAPLSHLE SRYLPAHFSP LVFFLLLSIM MACCLVAFFV
     LQRQPRCWEA SVEDLLNDQV TLHSIRPREE NDLGPAGTVD SSQGQGYLEE KAAPCCPAHL
     AFIYTLVAFV NALTNGMLPS VQTYSCLSYG PVAYHLAATL SIVANPLASL VSMFLPNRSL
     LFLGVLSVLG TCFGGYNMAM AVMSPCPLLQ GHWGGEVLIV ASWVLFSGCL SYVKVMLGVV
     LRDLSRSALL WCGAAVQLGS LLGALLMFPL VNVLRLFSSA DFCNLHCPA
//
